PAR 2.38% 20.5¢ paradigm biopharmaceuticals limited..

Ann: Paradigm Reports Australian Patent Acceptance, page-23

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,152 Posts.
    lightbulb Created with Sketch. 201
    On the other hand we have evidence that it has been life changing for people have used it and seen MRI based evidence to show that it can have a significant impact on the disease and the quality of life for people suffering From OA.

    I am happy to rely on the Phase 2 data and the anecdotal evidence that indicates it could be DMOAD. And will wait for further scientific data from the company.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.